AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7861247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 592
Study 2166377 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg enoxaparin
Number of subjects: 20
Study 2166377 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg enoxaparin
Number of subjects: 20
Study 6178567 — intervention group
Group type: EXPERIMENTAL
Intervention: Methisoprinol (4 g/day per os in 4 divided doses for 2 weeks)
Number of subjects: 63
Study 6178567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 6178567 — intervention group
Group type: COMPARATOR
Intervention: Normo- or hypo-ergic patients (not treated with methysoprinol or placebo)
Number of subjects: 63
Study 30448878 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark roast coffee blend (500 ml per day)
Number of subjects: 100
Study 30448878 — intervention group
Group type: COMPARATOR
Intervention: Water (500 ml per day)
Number of subjects: 100
Study 29284402 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal activity tracker (Fitbit Charge 2)
Number of subjects: 200
Study 29284402 — intervention group
Group type: COMPARATOR
Intervention: Standard post hospital care
Number of subjects: 200
Study 26351838 — intervention group
Group type: EXPERIMENTAL
Intervention: myosignal feedback on a computer screen
Number of subjects: 36
Study 26351838 — intervention group
Group type: EXPERIMENTAL
Intervention: virtual myoelectric prosthetic hand
Number of subjects: 36
Study 26351838 — intervention group
Group type: EXPERIMENTAL
Intervention: computer game
Number of subjects: 36
Study 26351838 — intervention group
Group type: EXPERIMENTAL
Intervention: Training (all methods)
Number of subjects: 36
Study 24550191 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (SFAs) overfeeding (palm oil)
Number of subjects: 39
Study 24550191 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids (PUFAs) overfeeding (sunflower oil)
Number of subjects: 39
Study 22975068 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin synthesis administration
Number of subjects: 0
Study 22975068 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin replacement therapy during chemotherapy
Number of subjects: 0
Study 22975068 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin administration for controlling postoperative cytokine storm
Number of subjects: 0
Study 19414681 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all‐trans retinoic acid (ATRA) and chemotherapy, maintenance treatment, escalating doses of cytarabine, early administration of dexamethasone, and CNS prophylaxis.
Number of subjects: 902
Study 19414681 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrollment onto the APL 2000 trial and combined maintenance with ATRA and chemotherapy.
Number of subjects: 902
Study 19414681 — intervention group
Group type: COMPARATOR
Intervention: APL 93 trial (previous standard treatment).
Number of subjects: 902
Study 17615472 — intervention group
Group type: EXPERIMENTAL
Intervention: Insight-oriented nursing program
Number of subjects: 34
Study 17615472 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 15714899 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal short-term memory task using concrete and abstract words
Number of subjects: 14
Study 15714899 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal short-term memory task using phonologically similar and dissimilar words
Number of subjects: 14
Study 15714899 — intervention group
Group type: COMPARATOR
Intervention: Control group matched on digit span
Number of subjects: 14
Study 15714899 — intervention group
Group type: COMPARATOR
Intervention: Control group matched on vocabulary level
Number of subjects: 14
Study 12069980 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% acyclovir cream
Number of subjects: 1385
Study 12069980 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 1385
Study 10402283 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical compression device (FemoStop) with ultrasound guidance (G1)
Number of subjects: 38
Study 10402283 — intervention group
Group type: COMPARATOR
Intervention: Mechanical compression device (FemoStop) without ultrasound guidance (G2)
Number of subjects: 38
Study 7594328 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily for 8 weeks
Number of subjects: 39
Study 7594328 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 200 mg twice daily for 2 weeks and Lansoprazole 30 mg daily for 8 weeks
Number of subjects: 39
Study 1974743 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous medication
Number of subjects: 116
Study 1974743 — intervention group
Group type: COMPARATOR
Intervention: Targeted medication
Number of subjects: 116
Study 497077 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 0
Study 497077 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcuronium
Number of subjects: 0
Study 31069957 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal film
Number of subjects: 200
Study 31069957 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal ring
Number of subjects: 200
Study 31069957 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal insert (tablet)
Number of subjects: 200
Study 31069957 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal gel
Number of subjects: 200
Study 31069957 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand products (film, insert, gel)
Number of subjects: 200
Study 28716786 — intervention group
Group type: EXPERIMENTAL
Intervention: Online pulmonary rehabilitation (my-PR)
Number of subjects: 90
Study 28716786 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face pulmonary rehabilitation
Number of subjects: 90
Study 26372485 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP-NVP (maternal intrapartum sdNVP with a 7-day 'tail' of ZDV along with lamivudine, and infant NVP)
Number of subjects: 435
Study 26372485 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant-only NVP (maternal placebos for sdNVP and the 'tail', with infant NVP)
Number of subjects: 435
Study 26372485 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV/r (maternal LPV/r starting at 28 weeks)
Number of subjects: 435
Study 23388445 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned media from human amniotic epithelial cells (CM from HAECs)
Number of subjects: 18
Study 23388445 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone
Number of subjects: 18
Study 23388445 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 18
Study 21470913 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (endurance exercise and resistance training)
Number of subjects: 60
Study 19967619 — intervention group
Group type: EXPERIMENTAL
Intervention: Pico-Salax (sodium picosulphate with magnesium citrate), administered in two doses: one the evening before and one on the morning of the procedure
Number of subjects: 83
Study 19967619 — intervention group
Group type: COMPARATOR
Intervention: PEG‐ELS (polyethylene glycol with electrolyte solution), administered over 4 hours
Number of subjects: 83
Study 19967619 — intervention group
Group type: EXPERIMENTAL
Intervention: Pico-Salax
Number of subjects: 83
Study 19967619 — intervention group
Group type: COMPARATOR
Intervention: PEG‐ELS
Number of subjects: 83
Study 17432395 — intervention group
Group type: COMPARATOR
Intervention: C‐SE non‐etch
Number of subjects: 29
Study 17432395 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐SE etch
Number of subjects: 29
Study 15077265 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (10 mg/day)
Number of subjects: 81
Study 15077265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 11473861 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 0.25 microg/kg (Group R1)
Number of subjects: 120
Study 11473861 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 0.5 microg/kg (Group R2)
Number of subjects: 120
Study 11473861 — intervention group
Group type: COMPARATOR
Intervention: normal saline (Group P)
Number of subjects: 120
Study 9596201 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 30
Study 9596201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8001300 — intervention group
Group type: EXPERIMENTAL
Intervention: K-strophanthin (0.125 mg intravenously)
Number of subjects: 22
Study 8001300 — intervention group
Group type: COMPARATOR
Intervention: Digoxin (0.25 mg orally)
Number of subjects: 22
Study 2968749 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone sodium tetrahydrophthalate followed by oral prednisone for 2 days
Number of subjects: 9
Study 2968749 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone followed by oral 9 alpha fludrocortisone for 2 days
Number of subjects: 9
Study 31904685 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal stimulation via an esophageal stimulating catheter (E‐Motion Tube)
Number of subjects: 155
Study 31904685 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 155
Study 31568669 — intervention group
Group type: EXPERIMENTAL
Intervention: Online support forum participation
Number of subjects: 258
Study 27146798 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Therapy (MT)
Number of subjects: 66
Study 27146798 — intervention group
Group type: COMPARATOR
Intervention: Standard supportive treatment (Control Group)
Number of subjects: 66
Study 25060288 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored-print intervention (three computer-tailored newsletters)
Number of subjects: 330
Study 25060288 — intervention group
Group type: COMPARATOR
Intervention: Control (pamphlet detailing public health recommendations for physical activity)
Number of subjects: 330
Study 24266309 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic hemoclips therapy (group I)
Number of subjects: 70
Study 24266309 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of hemoclips and epinephrine (group II)
Number of subjects: 70
Study 21531453 — intervention group
Group type: EXPERIMENTAL
Intervention: ZrO(2), modified via novel 3.2 nm silica layer/silane‐treated
Number of subjects: 12
Study 21531453 — intervention group
Group type: EXPERIMENTAL
Intervention: ZrO(2), modified via novel 5.8 nm silica layer/silane‐treated
Number of subjects: 12
Study 21531453 — intervention group
Group type: EXPERIMENTAL
Intervention: ZrO(2), modified via novel 30.4 nm silica layer/silane‐treated
Number of subjects: 12
Study 21531453 — intervention group
Group type: EXPERIMENTAL
Intervention: HF‐etched/silane‐treated ZrO(2)
Number of subjects: 12
Study 21531453 — intervention group
Group type: EXPERIMENTAL
Intervention: Primer‐treated ZrO(2)
Number of subjects: 12
Study 21531453 — intervention group
Group type: COMPARATOR
Intervention: Porcelain (control)
Number of subjects: 12
Study 18695787 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia educational computer program
Number of subjects: 35
Study 18695787 — intervention group
Group type: COMPARATOR
Intervention: Traditional theoretical class
Number of subjects: 35
Study 16449027 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-I at 80 microg/kg body weight daily (n = 6)
Number of subjects: 18
Study 16449027 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-I at 40 microg/kg twice daily (n = 6)
Number of subjects: 18
Study 16449027 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-I at 80 microg/kg twice daily (n = 6)
Number of subjects: 18
Study 16449027 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 18
Study 12566183 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory epidural analgesia (intermittent epidural injections of 0.1% ropivacaine with 0.6 microg/ml sufentanil)
Number of subjects: 221
Study 12566183 — intervention group
Group type: COMPARATOR
Intervention: Non-ambulatory epidural analgesia (intermittent epidural injections of 0.1% ropivacaine with 0.6 microg/ml sufentanil)
Number of subjects: 221
Study 12566183 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory epidural analgesia
Number of subjects: 221
Study 12566183 — intervention group
Group type: COMPARATOR
Intervention: Non-ambulatory epidural analgesia
Number of subjects: 221
Study 10693153 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of d,l‐fenfluramine (intervention group: bulimia nervosa remitted)
Number of subjects: 21
Study 10693153 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group: healthy controls)
Number of subjects: 21
Study 10693153 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of d,l‐fenfluramine (intervention group: current bulimia nervosa)
Number of subjects: 21
Study 9497949 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit intervention in one hospital
Number of subjects: 0
Study 9497949 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit intervention focusing on three target objectives
Number of subjects: 0
Study 9497949 — intervention group
Group type: COMPARATOR
Intervention: Control hospitals (no audit intervention)
Number of subjects: 0
Study 10412478 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive Amalgam Restorations (EAR) with five different auxiliary retention methods.
Number of subjects: 300
Study 3518980 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg sublingual)
Number of subjects: 32
Study 3518980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 31403695 — intervention group
Group type: EXPERIMENTAL
Intervention: E-liquids with PG/VG ratio 70/30
Number of subjects: 30
Study 31403695 — intervention group
Group type: EXPERIMENTAL
Intervention: E-liquids with PG/VG ratio 50/50
Number of subjects: 30
Study 31403695 — intervention group
Group type: EXPERIMENTAL
Intervention: E-liquids with PG/VG ratio 0/100
Number of subjects: 30
Study 30535217 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 μg of oral alfacalcidol per day (intervention group; n=495)
Number of subjects: 976
Study 30535217 — intervention group
Group type: COMPARATOR
Intervention: Treatment without vitamin D receptor activators (control group; n=481)
Number of subjects: 976
Study 26995361 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness Management and Recovery (IMR)
Number of subjects: 200
Study 26995361 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 200
Study 26467790 — intervention group
Group type: EXPERIMENTAL
Intervention: 650 mg acetaminophen
Number of subjects: 321
Study 26467790 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen
Number of subjects: 321
Study 26467790 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg meloxicam
Number of subjects: 321
Study 23648081 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil 50 mg (group FT)
Number of subjects: 80
Study 23648081 — intervention group
Group type: COMPARATOR
Intervention: Control group (group CP)
Number of subjects: 80
Study 23648081 — intervention group
Group type: COMPARATOR
Intervention: Control group (group CT)
Number of subjects: 80
Study 20959485 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical clustering of HPV genotype patterns
Number of subjects: 2780
Study 20959485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 1 (CIN3 histology with abnormal cytology)
Number of subjects: 2780
Study 20959485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 2 (CIN3 histology with normal cytology)
Number of subjects: 2780
Study 20959485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 3 (Older women with normal/low-grade histology)
Number of subjects: 2780
Study 20959485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 4 (Younger women with low-grade histology)
Number of subjects: 2780
Study 20959485 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV genotype group 1
Number of subjects: 2780
Study 20959485 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV genotype group 2
Number of subjects: 2780
Study 20959485 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV genotype group 3
Number of subjects: 2780
Study 20959485 — intervention group
Group type: COMPARATOR
Intervention: Colposcopy
Number of subjects: 2780
Study 18990046 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 weeks of 2 different chiropractic techniques
Number of subjects: 432
Study 18990046 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 weeks of 2 different chiropractic techniques
Number of subjects: 432
Study 18990046 — intervention group
Group type: COMPARATOR
Intervention: Medical care consisting of 3 provider visits for medications
Number of subjects: 432
Study 18990046 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 432
Study 16906017 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil at concentrations of 0, 33.33, 66.67, and 100 ng/ml
Number of subjects: 20
Study 14516427 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined surgery group (360 degrees scleral buckling, pars plana vitrectomy, air-fluid exchange, endolaser, injection of 14% perfluoropropane gas)
Number of subjects: 44
Study 14516427 — intervention group
Group type: COMPARATOR
Intervention: Scleral buckling group (360 degrees scleral buckling, cryopexy, external subretinal fluid drainage)
Number of subjects: 44
Study 14516427 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined surgery group
Number of subjects: 44
Study 14516427 — intervention group
Group type: COMPARATOR
Intervention: Scleral buckling group
Number of subjects: 44
Study 10905242 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular inhaled salbutamol 400 microg four times daily for 12 months
Number of subjects: 983
Study 10905242 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 983
Study 10905242 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular inhaled salbutamol 400 microg four times daily
Number of subjects: 983
Study 9216092 — intervention group
Group type: EXPERIMENTAL
Intervention: TT5 (5 days treatment with furazolidone 600 mg/day, metronidazole 750 mg/day, amoxicillin 1.5 g/day)
Number of subjects: 54
Study 9216092 — intervention group
Group type: EXPERIMENTAL
Intervention: TT10 (10 days treatment with furazolidone 600 mg/day, metronidazole 750 mg/day, amoxicillin 1.5 g/day)
Number of subjects: 54
Study 9216092 — intervention group
Group type: COMPARATOR
Intervention: All patients (combined analysis)
Number of subjects: 54
Study 1596304 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin with a low fat diet
Number of subjects: 19
Study 1596304 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin with a high fat diet
Number of subjects: 19
Study 1596304 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 19
Study 6712199 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin, 4 g every 6 h
Number of subjects: 18
Study 6712199 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenicillin, 7.5 g every 6 h
Number of subjects: 18
Study 6712199 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 0.9% NaCl, 50 ml every 6 h
Number of subjects: 18
Study 31672143 — intervention group
Group type: EXPERIMENTAL
Intervention: enteral Levetiracetam (eLVT)
Number of subjects: 30
Study 31672143 — intervention group
Group type: COMPARATOR
Intervention: phenobarbital
Number of subjects: 30
Study 31672143 — intervention group
Group type: EXPERIMENTAL
Intervention: eLVT
Number of subjects: 30
Study 27989864 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence visualization by inexperienced examiner
Number of subjects: 15
Study 27989864 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence visualization by expert professional
Number of subjects: 15
Study 27989864 — intervention group
Group type: COMPARATOR
Intervention: Conventional white light examination by inexperienced examiner
Number of subjects: 15
Study 27989864 — intervention group
Group type: COMPARATOR
Intervention: Conventional white light examination by expert professional
Number of subjects: 15
Study 25661298 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 6103
Study 25661298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6103
Study 23982113 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 (1.8 g daily for 12 weeks)
Number of subjects: 355
Study 23982113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study 23982113 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3
Number of subjects: 355
Study 22851558 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + PCV
Number of subjects: 251
Study 22851558 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 251
Study 19683191 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 0.25% (twice daily)
Number of subjects: 105
Study 19683191 — intervention group
Group type: EXPERIMENTAL
Intervention: TGFS 0.25% (daily)
Number of subjects: 105
Study 19683191 — intervention group
Group type: EXPERIMENTAL
Intervention: TGFS 0.5% (daily)
Number of subjects: 105
Study 17532892 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified 30-item assessment (after removal of reflex items)
Number of subjects: 512
Study 17532892 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasch item-fit statistics
Number of subjects: 512
Study 17532892 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasch-generated item-difficulty order
Number of subjects: 512
Study 15887019 — intervention group
Group type: EXPERIMENTAL
Intervention: Nationwide interdisciplinary preventive programme targeting reduction of exposure to powdered high-protein latex gloves.
Number of subjects: 884
Study 15920212 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4 (6%)
Number of subjects: 31
Study 15920212 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 200/0.5 (6%)
Number of subjects: 31
Study 10589178 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular stent-graft repair
Number of subjects: 150
Study 8913399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 500 mg in 2 mL of lidocaine 1% solution (250 mg/mL)
Number of subjects: 17
Study 8913399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 500 mg in 1.4 mL of lidocaine 1% solution (350 mg/mL)
Number of subjects: 17
Study 1862788 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day desipramine
Number of subjects: 54
Study 1862788 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day amantadine-placebo
Number of subjects: 54
Study 1862788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54